Opinion|Videos|February 24, 2025
Sequencing Treatment for Endocrine-Resistant Disease
With Kevin Kalinsky, MD, the Oncology Brothers discuss sequencing treatment for endocrine-resistant diseases, which involves using a strategic approach to combat resistance to hormonal therapies. It includes combining therapies such as CDK4/6 inhibitors, mTOR inhibitors, and chemotherapy, aiming to overcome resistance and improve patient outcomes.
Advertisement
Advertisement
Related to this article
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
2
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
3
FDA OKs Pirtobrutinib in Frontline CLL/SLL
4
How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?
5